Only one year after its establishment, it has cooperated with Gilead and Baekje, holding more than 300 million US dollars. Why is this cutting-edge cell therapy being sought after?

Since the first CAR-T product was approved in 2017, tumor immunotherapy has ushered in the era of cell therapy following the blockade of immune checkpoints

On November 2, Shoreline Biosciences, a cutting-edge in the field of iPSC cell therapy, announced that it has received a US$140 million financing led by Ally Bridge Group.

Source: Shoreline official website

Founded in 2020, Shoreline Biosciences is a biotechnology company headquartered in San Diego, California.

In June of this year, Shoreline won the favor of Gilead’s Kite Pharma and BeiGene, and reached two important cooperations

Shoreline's iPSC technology platform (Source: Shoreline official website)

Shoreline genetically engineered iPSCs to generate a series of iPSC cell lines, which can be expanded and differentiated into NK cells or macrophages when needed, thereby providing a very consistent cell therapy

Shoreline CEO Dr.

Dr.

In addition to Shoreline, American biotechnology companies Century Therapeutics, Fate Therapeutics, and domestic companies such as Saiyuan Biology are all developing iPSC-derived cell therapies for cancer

FT596 clinical data (source: Fate official website)

The clinical data of FT516 combined with rituximab in patients with r/r BCL showed that of 11 patients receiving treatment, 8 had an objective remission (ORR=73%) and 6 had a complete remission (CRR=55%).

FT516 clinical data (source: Fate official website)

Frank Yu, the founder/CEO of Huiqiao Capital, who led this round of Shoreline financing, said that they have been investigating the field of iPSC-derived NK cell therapy for many years, and that this field has made encouraging clinical progress.

Reference materials:

[1] Shoreline Biosciences Announces $140M Financing To Advance PipelineOf Next Generation Cell Immunotherapies.